SHG Shares Singular Health Group Ltd
ASX · ASXLast in our picks 2026-09-23 — not in the current list; analysis below is from that screen
Emerging digital-health biotech with strong speculative upside if commercialization accelerates.
Future value: $0.27 (+50.00%) · 6-12 months
Signal breakdown
- ▸Strong recent return momentum, but still early stage.
- ▾Below 50-day MA (-5.09%)
- ▾Near 52-week low (5.7% of range)
- ▸~50% upside to price target
Is SHG a buy right now?
Trend: SHG is trading below the 50-day average (-8.33%), RSI 56 — neutral momentum, with a 3-month return of -17.50%.
Valuation & quality: Singular Health Group Ltd trades on forward P/E -47.1, price-to-book 5.00; fundamentals show net margin 0.0%, return on equity -53.7%, revenue growth 194.6% year on year.
Analyst consensus: 1 analysts have a mean 12-month price target of A$0.31 (+87.9% vs the last close; range A$0.31 – A$0.31), consensus rating “none”.
Our screen: ACCUMULATE (score 1) — Emerging digital-health biotech with strong speculative upside if commercialization accelerates.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -15.40% | +0.00% | -13.60% | +15.80% | -13.60% | +0.00% | -10.50% | +0.00% |
Fundamentals
Analyst price target
Technical signals
About Singular Health Group Ltd
Singular Health Group Ltd, operates as a healthcare technology company in Australia. The company Volumetric Rendering Platform, a proprietary technology that enhances the visualization of patient anatomy and health issues by converting 2D images from CT, MRI, and PET scans into 3D models.
Sector: Healthcare · Industry: Health Information Services · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.